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Background: Contradictory information exists regarding the inﬂuence of CYP2D6polymorphisms on adverse drug
reactions (ADRs) (extrapyramidal symptoms (EPS) and weight gain) related to risperidone treatment. This
prompted us to evaluate the inﬂuence of CYP2D6 genetic variation in a cohort of South African patients who
presented with marked movement disorders and/or weight gain while on risperidone treatment.
Methods: Patients who were experiencing marked risperidone ADRs were recruited from Weskoppies Public
Psychiatric Hospital. As poor or intermediate metabolism was expected, comprehensive CYP2D6 sequence
variations were evaluated using XL-PCR + Sequencing.
Results: No statistically signiﬁcant association was found between CYP2D6 poor metabolism and risperidone
ADRs. An inverse relationship between EPS and weight gain was however identiﬁed. A novel CYP2D6 allele
was identiﬁed which is unlikely to affect metabolism based on in silico evaluation.
Conclusion: CYP2D6 variation appeared not to be a good pharmacogenetic marker for predicting risperidone-
related ADRs in this naturalistic South African cohort. Evaluation of a larger cohort would be needed to conﬁrm
these observations, including an examination of the role of potential intermediaries between the hypothesised
genetic and clinical phenotypes.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atypical antipsychotic medication has largely superseded typical or
classical antipsychotics for the treatment of schizophrenia in the last
two decades. This is largely due to improved efﬁcacy in treating nega-
tive symptoms of schizophrenia as well as a more favourable side effect
proﬁle (less extrapyramidal symptoms and tardive dyskinesia). Demon-
strating antagonism at 5-hydroxytryptamine (5-HT2) and dopamine
(D2) receptors (Janssen et al., 1988; Leysen et al., 1988), risperidone is
an atypical antipsychotic which improves both positive and negative
symptoms of schizophrenia (Singam et al., 2011). Risperidone is also
registered for the treatment of manic episodes of bipolar disorder and
for irritability associated with autistic disorder. Off-label uses include
behavioural problems in dementia, refractory or psychotic majory, P.O. Box 2034, Pretoria 0001,
46.
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. This is an open access article underdepressive disorder, refractory obsessive–compulsive disorder and
Tourette's disorder, among others (Shekelle et al., 2007). The range of
patients receiving atypical antipsychotic treatment (including risperi-
done) for a variety of different indications is vast and includes children
(Lazzeretti et al., 2011) as well as the elderly (Burke and Tariot, 2009).
Although the atypical antipsychotics have an improved side effect
proﬁle, adverse drug reactions (ADRs) still pose a challenge. Genetic
polymorphisms and environmental inﬂuences are typically implicated
in ADRs. A study of 500 French patients taking risperidone revealed
that dosage adjustments were needed in 61% of patients due to the ef-
fects of co-medication and 10% as a result of genetic factors (Martin
et al., 2004). Understanding the contribution of environmental factors,
particularly drug–drug interactions resulting frompolypharmacy (com-
mon in psychiatry treatment), and also of genetic inﬂuences, may assist
in reducingADRs. Environmental factorswill persist as long as the factor
is present, and can often be modiﬁed. However, genetic inﬂuences are
permanent and need to be accounted for (de Leon et al., 2008).
One of the most important genetic factors inﬂuencing risperidone
pharmacokinetics is phase I metabolism mediated predominantly by
CYP2D6 (Fleeman et al., 2011). CYP2D6 is a highly polymorphic genethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cyp2d6.htm). Many of these alleles have been found to alter enzyme
function, ranging from absent to increased. Of these alleles, the non-
functional CYP2D6*4 allele is particularly frequent in individuals of
European origin (Sistonen et al., 2009) and *5 is found in the Coloured
and Xhosa populations of South African (Gaedigk and Coetsee, 2008;
Wright et al., 2010). Frequent decreased function alleles include
CYP2D6*10 in East Asians, *17 and *29 in Black Africans and *41 in
Europeans as well as in western and southern Asians (Sistonen et al.,
2009). Multiple copies of functional CYP2D6 genes are frequent in
much of Africa (Alessandrini et al., 2013). The CYP2D6 alleles cause
inter-individual variations in metabolism which are classiﬁed as poor
(PM), intermediate (IM), extensive (EM) and ultra-rapid (UM). This
may form a vital tool for improving efﬁcacy and reducing ADRs by
predicting phenotype i.e.metabolism.
Weight gain is another important ADR of risperidone (Nasrallah,
2008). Weight gain results in reduced patient compliance irrespective
of symptomatic improvement (Nasrallah, 2006). Although there is
very little known about the association between CYP2D6 polymor-
phisms andweight gain, Lane et al. (2006) observed a signiﬁcant corre-
lation between the *10 allele and weight gain in risperidone-treated
patients.
In light of contradicting data on CYP2D6 pharmacogenetics and ris-
peridoneADRs (Fleeman et al., 2011), and given the great genetic diver-
sity of southern African populations, this pilot study was aimed at
addressing this relationship in a small cohort of South African patients.
CYP2D6 genotype was analysed in a risperidone treated cohort selected
on the basis of risperidone ADRs, speciﬁcally movement disorders and
weight gain. Notwithstanding intermediaries between the genetic
phenotype of poor metabolisers and the clinical phenotype of ADRs,
the aim of this pilot study was to examine whether a predicted
CYP2D6 PM phenotype would emerge in a naturalistic cohort for
which such phenotype would bemost likely, i.e. a cohort with clinically
marked movement disorders and/or weight gain.
2. Materials and methods
2.1. Patient cohort
Approval was obtained from the Research Ethics Committee, Faculty
of Health Sciences, University of Pretoria and the study was performed
according to the stipulations of the Declaration of Helsinki. Written
informed consent was obtained from all patients. Inpatients or outpa-
tients at Weskoppies Public Psychiatric Hospital (Pretoria, South
Africa) receiving risperidone treatment were recruited if they experi-
enced a clinically marked risperidone related movement disorder and/
or weight gain as had been recorded in their clinical notes before re-
cruitment to the study. A cohort was thus purposively gathered for
which a link between clinical phenotype (of marked ADRs) and genetic
phenotype (of a PMnature)might be present. A naturalistic cohort of 24
patients older than 17 years of age, who gave informed consent, who
were of any race and either gender, irrespective of their psychiatric di-
agnosis and irrespective of whether they used concomitant medication,
was gathered, except for excluding patients concomitantly on an anti-
psychotic medication other than risperidone. Patients suffering from
neurological disorders that may be mistaken for risperidone related
ADRs were excluded from the cohort. On the day of recruitment, one
of the collaborating psychiatrists (MD level) performed clinical mea-
sures of the ADRs and drew two venous blood samples in ethylenedi-
aminetetraacetic acid (EDTA) vacutainer tubes (Becton-Dickinson,
Franklin Lakes, NJ, USA) for CYP2D6 genotypic evaluation.
2.2. Phenotypic evaluation
ADRs resulting from risperidone treatment were measured as clini-
cal phenotype in this study. Two distinct and prominent ADRs weremeasured: weight gain andmovement disorders. If either prompted in-
clusion into the study, weight gained from the onset of risperidone
treatment until the time of recruitment was recorded as a continuous
variable. Dyskinesia (irrespective ofwhether acute or tardive)wasmea-
sured using the Abnormal Involuntary Movement Scale (AIMS, Munetz
and Benjamin, 1988), akathisia using the Barnes Akathisia Scale (BAS,
Barnes, 1989) and Parkinsonism using the Simpson-Angus Scale (SAS,
Simpson and Angus, 1970). No patients suffered from acute dystonia
at the time of measurement.
2.3. CYP2D6 genotyping
Genomic DNA (gDNA) was extracted from whole blood using the
automated Maxwell® 16 system (Promega, Madison, WI, USA) accord-
ing to instructions. Genotyping was performed using a CYP2D6 XL-
PCR + Sequencing strategy as previously described (Dodgen et al.,
2013). Brieﬂy, the strategy makes use of two duplex long-range PCR
(polymerase chain reaction) assays, one for CYP2D6*5 (complete gene
deletion) and the other for duplication detection followed by CYP2D6
gene sequencing for allele determination. CYP2D6 gene sequencing
was performed by Inqaba Biotechnological Industries (Pretoria, South
Africa) using 3130XL and 3500XL (Applied Biosystems) instruments.
PCR products were puriﬁed using FastAP Thermosensitive Alkaline
Phosphatase (Fermentas Life Science) according to the manufacturer's
instructions. The ABI Big Dye Terminator Cycle Sequencing kit version
3.1 (Applied Biosystems) and appropriate CYP2D6 sequencing primers
were used for sequencing reactions.
Resulting electropherograms were edited using FinchTV version
1.4.0 (Copyright © 2004–2006, Geospiza Inc.) and compared to the
AY545216 (GenBank) in CLC DNA Workbench version 5.5 (CLC bio,
Aarhus, Denmark) software for polymorphism identiﬁcation. Single nu-
cleotide polymorphisms (SNPs) were numbered according to M33388
(GenBank) and alleles identiﬁed according to the Human CYP Nomen-
clature website for CYP2D6 (http://www.cypalleles.ki.se/index.htm).
The novel polymorphismwas cloned using the CloneJET™ PCR Clon-
ing Kit (Fermentas Life Science) according to the manufacturer's
instructions and transformed into DH5α cells (Zymo Research, Orange,
CA, USA). Colonies were screened by amplifying the region of interest
(where the novel SNP was located). Once the novel SNP was found
the clone was ampliﬁed and re-sequenced. The novel SNP was evaluat-
ed using in silico software, Sorting Intolerant from Tolerant (SIFT) and
PolyPhen prediction software to estimate the potential effect on
CYP2D6 activity (Ramensky et al., 2002; Ng and Henikoff, 2003). The
novel allele has been submitted to the Human CYP Nomenclature com-
mittee for CYP2D6 allele designation.
2.4. CYP2D6 enzyme activity prediction
An adjusted version of the Activity Score (AS) system (Gaedigk et al.,
2008) was used to predict CYP2D6 phenotype. The adjusted phenotype
prediction systemwas adopted from genotype–phenotype comparisons
described byDodgen et al. (2013),where activity is Increased=2.0, Nor-
mal= 1.0, Decreased= 0.5 and None= 0.0 using information from the
Human Cytochrome P450 (CYP) Allele Nomenclature Committee's on-
line database for CYP2D6. CYP2D6*17, traditionally assigned an AS of
0.5, was given a score of 1.0, as this allele has been found to metabolise
risperidone with full function (de Leon et al., 2009). If no information
on phenotypic activity was available, the allele was assigned a score of
1.0. Summation of genotypic scores (e.g.*2 / *41=1.0+ 0.5= 1.5) pre-
dicted phenotype as PM = 0.5, IM = 0.5–1.0, EM = 1.5–2.0 and
UM N 2.0.
2.5. Statistical analyses
Tools for Population Genetic Analysis (TFPGA) software v1.3 was
used to test allele deviation from Hardy–Weinberg equilibrium using
Table 2
CYP2D6 genotype andpredictedphenotype frequencies in a cohort of South African risper-
idone treated patients experiencing ADRs.
Genotype AS Predicted phenotype Number (n= 24) Ethnicity
*1/*1
2.0
EM
1 White
*1/*17 1 Black
*1/*2 2 Black
*2/*106 1 Black
*2/*2 2 White
*2/*43 1 Black
*1/*29
1.5
1 Black
*2/*41 1 White
*35/*41 1 White
*1/*4
1.0
IM
5 4 W/1 B
*2/*4 1 White
*2/*6B 1 White
*4/*35 1 White
*5/*17 1 Black
*5/*41
0.5
1 White
*5/10B 2 Black
*4/*4 0.0 PM 1 White
ADRs, adverse drug reactions; AS, risperidonemodiﬁed version of the activity score system
(Gaedigk et al., 2008); EM, extensivemetabolism; IM, intermediatemetabolism; PM, poor
metabolism.
42 T.M. Dodgen et al. / Applied & Translational Genomics 5 (2015) 40–46Fisher's exact test (Miller, 1997). Additional statistical evaluations were
calculated using SPSS version 20.0 (SPSS Inc., Chicago, Ill). As a normal
distribution of data could not be assumed, nonparametric tests were
used for comparison. The Mann–Whitney test was used following
cross tabulation to compare sex and race (Black African orWhite Cauca-
sian) to ADRs. The Kruskal–Wallis test, using the Chi-square, was used
to compare predicted phenotype with each risperidone movement
disorder experienced as well as weight gained (ADRs). Kendall's tau-b
was used to compare age, number of cigarettes smoked, risperidone
dosage, and each ADR to the other. Concomitantmedication, anticholin-
ergic medication, sex and race were evaluated as confounding inﬂu-
ences of risperidone ADRs using the Mann–Whitney test. P values of
b0.05 were considered signiﬁcant.
3. Results
3.1. Patient characteristics
The observed characteristics for the cohort of 24 risperidone-treated
patients experiencing movement disorders and/or weight gain are pre-
sented in Table 1. Parkinsonism (SAS, n= 18) appeared to be the most
commonly experienced ADR followed closely by dyskinesia (AIMS, n=
17). Eight of the patients were included by virtue of their clinically
marked weight gain, of which two also experienced simultaneous move-
ment disorders, but in both these cases theweight gainwas less than 5 kg.
None of the patients admitted to the use of cannabis at the time of
sampling. Eight patientswere prescribed risperidonemonotherapy. Con-
comitantly prescribed anticholinergicmedication includedorphenadrine
(n= 5) and biperidine (n= 3). Additional concomitant medication at
the time of sampling included sodium valproate (n= 8), lithium (n=
4), oxazepam (n = 4), clonazepam (n = 3), cyproteroneacetate (n =
2),ﬂuoxetine (n=2), propranolol (n=2), thyroxin (n=2), venlafaxine
hydrochloride (n=2), carbamazepine (n=1), citalopram (n=1), hy-
droxyzine (n=1), imipramine (n=1),metformin (n=1), omeprazole
(n= 1), paroxetine (n= 1) and perindopril (n= 1).
3.2. CYP2D6 genotype and predicted phenotype
All CYP2D6 alleles identiﬁed were in Hardy–Weinberg equilibrium.
Of the 12 different CYP2D6 alleles identiﬁed (Table 2), three were
responsible for absent enzyme function (*4, *5 and *6B), four were
responsible for reduced enzyme function (*10B, *17, *29 and *41) and
one novel allele was identiﬁed. No duplications (functional or non-Table 1
Descriptive statistical data for a pilot cohort of risperidone-treated South African patients (n=
Descriptive statistics Com
P-v
Number Mean SD Range AIM
Female/male 8/16 0.6
Black/white 9/15 0.0
Age 32.9 12.4 18–61 0.3
Cigarettes (per day) 11a 9.0 9.1 0–20 0.1
Dosage (mg/day) 3.9 1.8 1–7 0.7
Adverse drug reactions (ADRs)
AIMS (max = 40) 8.0 7.6 0–22 –
BAS (max = 14) 2.1 3.6 0–11
SAS (max = 40) 7.2 6.7 0–20
Weight gained (WG) 6.9 13.3 0–45
CYP2D6 predicted phenotype
PM 4 0.8
IM 9
EM 11
a More than 10 cigarettes per day. ADRswere compared to sex and race using theMann–Wh
smoked and dosage using Kendall's tau-b. The Kruskal–Wallis test was used to evaluate whethe
the difference is, but whether or not there is a statistical difference at all. In this case a P-value is
Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Scale (BAS) and the Simpfunctional) were identiﬁed. Table 2 also shows the genotypes observed,
theAS scores and predicted phenotype. PMwas predicted in one patient
(4.2%), 12 were IM (50.0%) and 11 were EM (45.8%). There were no
UM's predicted in this cohort.
3.3. Novel allele
Fig. 1 illustrates the novel allele identiﬁed in this cohort. The non-
synonymous 3877GNASNPwas identiﬁed in exon8with a *1 backbone.
This SNP resulted in amino acid change E418K. No functional difference
was found by in silico PolyPhen software, predicting the amino acid
change to be benign with a PSIC score of 1.178. A second in silico
prediction by SIFT software agreed with PolyPhen predicting that this
mutation would be tolerated with a SIFT score of 0.13.
3.4. Risperidone ADRs and CYP2D6 inﬂuence
None of the individual risperidone-associated movement disorders
were found simultaneously, as correlation coefﬁcients were poor and
P values were all above 0.23 (refer to Table 1). This suggests that24) experiencing ADRs, and evaluation of related and confounding factors.
parative statistics
alue (correlation coefﬁcient if applicable)
S BAS SAS WG
37 0.182 0.038 0.928
86 0.656 0.694 0.227
31 (0.150) 0.709 (−0.062) 0.289 (0.161) 0.699 (0.063)
24 (−0.257) 0.670 (0.077) 0.175 (−0.224) 0.259 (0.200)
14 (−0.060) 0.703 (−0.067) 0.642 (0.074) 0.903 (0.021)
0.291 (0.182) 0.233 (0.189) 0.004 (−0.484)
– 0.752 (0.054) 0.458 (−0.136)
– 0.010 (−0.435)
–
41 0.797 0.335 0.855
itney test. ADR occurrenceswere evaluated for correlationwith other ADRs, age, cigarettes
r predicted phenotypes signiﬁcantly inﬂuence each ADR. This test does not identify where
generated per ADR and not per predicted phenotype.Movement disordersmeasured using
son-Angus Scale (SAS).
Fig. 1. Comparison of the novel CYP2D6 alleles identiﬁed in this cohort to similar alleles. M33388 and AY545216 reference sequences were used for numbering and as CYP2D6*1 respec-
tively. Black boxes represent sequence variation at a speciﬁc locus. A star in a black box represents a novel SNP resulting in non-synonymous amino acid changes and thus allele deﬁning
(or sub-variant deﬁning) SNPs, and an x represents regions not sequenced.M33388, AY545216 and CYP2D6*2A are depicted as presented on theNomenclature Committeewebsite (www.
cypalleles.ki.se) or as represented by Gaedigk et al. (2007).
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of risperidone therapy are independent of one another. A strong negative
correlation of −0.484 was found between weight gain and akathisia
(P= 0.004) and−0.435 between weight gain and parkinsonian symp-
toms (P= 0.010). This suggests that when weight gain is experienced,
the patient is unlikely to experience akathesia or parkinsonism and vice
versa. Tardive diskinesia had a weak correlation of−0.136 with weight
gain (P = 0.458), and therefore may not share the same relationship
with weight gain as the other risperidone movement disorders. When
CYP2D6 predicted phenotype was compared to risperidone ADRs, no sta-
tistical association was found, with P values ≥ 0.335 (Table 1).
3.5. Confounding variables which may be associated with risperidone ADRs
Neither concomitant medication (P ≥ 0.081) nor the number of
cigarettes smoked (P ≥ 0.124; Table 1) were found to inﬂuence risperi-
done ADRs. Age, race, gender and sex appeared not to be associated
with risperidone ADRs with P values ≥ 0.086 (refer to Table 1). Sex cor-
related well with symptoms of parkinsonism (P = 0.038), suggesting
that women are more likely to experience parkinsonism than men
when treated with risperidone. Although not statistically signiﬁcant
(P = 0.086), the Black African portion of the cohort was apparently
more susceptible to dyskinesia. The latter two comparisons need to be
interpreted with caution as the sample size in this cohort was small
and a larger cohort will need to be sampled to conﬁrm the association.
4. Discussion
4.1. CYP2D6 genetics
As all alleles were in Hardy–Weinberg equilibrium, the CYP2D6
screening assay using XL-PCR + Sequencing appears to be accurateand comprehensive for CYP2D6 allele identiﬁcation in this cohort.
CYP2D6*4, *6B (absent function) and *41 (reduced function) were ob-
served in Caucasians, while *17 and *29 (both reduced function) were
observed in Black Africans. One Black African individual was heterozy-
gous for CYP2D6*4, an allele which is observed at low frequency in
African populations (Sistonen et al., 2009). CYP2D6*10B (reduced func-
tion) has been found at high frequency in African populations (Matimba
et al., 2009). It is therefore not surprising to ﬁnd CYP2D6*10B in Black
Africans in this cohort. CYP2D6*5 was found in both Black Africans and
Caucasians which agrees with what has been observed in cohorts of
varying ethnicity (Sistonen et al., 2009). The novel allele identiﬁed
was observed in a Black African individual, emphasising the importance
of comprehensive genetic screening methods to accommodate low fre-
quency alleleswhichmay be of clinical relevance (Matimba et al., 2009).
Conﬁdence in the genotyping assay used, including copy number dis-
crepancies, was validated by Dodgen et al. (2013) in which potential
for bias or analytical error was addressed. As the sample size of each
ethnic groups is small, allele frequencies will not be considered in this
pilot cohort.
Although the novel allele was evaluated using in silico evaluation of
change in enzyme activity, further in vitro or in vivo experiments will
need to be conducted for conﬁrmation.
4.2. CYP2D6 and risperidone movement disorders
The sampled cohort was selected for having marked risperidone-
related ADRs (risperidone induced movement disorders and weight
gain), Although the signiﬁcance of CYP2D6 polymorphisms affecting ris-
peridone metabolism in both drug naïve and experienced patients has
been well established (Jovanovic et al., 2010), it is still unclear whether
genetic mutations in CYP2D6 are associated with ADRs. If the link be-
tween reduced risperidonemetabolism by CYP2D6 PMs andmovement
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2005a; Bozina et al., 2008), the majority of this cohort would have
been expected to be PMs. This was not the case, as only 4.2% (1/24)
were PMs. This frequency for PMs has been similarly observed in vari-
ous volunteer based southern African cohorts (Matimba et al., 2009;
Wright et al., 2010; Dodgen et al., 2013). Half of the cohort was IMs
and this should be investigated further as a potential explanation for
ADRs.
Little research has been published on the association between ris-
peridone induced movement disorders and CYP2D6 polymorphisms
and contradictory ﬁndings are apparent. The majority ﬁnd no support
for the association (Jovanovic et al., 2010), agreeing with what was ob-
served in this study. This lack of association could be similar to the ob-
served poor correlation between CYP2D6 polymorphisms, risperidone
active moiety and clinical response measured as prolactin levels re-
leased due to dopamine receptor occupation (Wang et al., 2007).
Although the plasma concentration of risperidone has been found to
be higher in PM's and 9-hydroxyrisperidone is higher in EM's, the total
active moiety (the sum of both) appears not to vary much between
metaboliser classes (Novalbos et al., 2010). It has therefore been pro-
posed that CYP2D6 metabolism is unlikely to be of clinical relevance
in terms of efﬁcacy.
Conﬂicting results have also been reported, where increased risper-
idone active moiety was found in CYP2D6 predicted PMs compared to
EMs (Locatelli et al., 2010). This, combined with the suggestion by de
Leon et al. (2008), that risperidone and 9-hydroxyrisperidone are not
equipotent (risperidone having greater activity), may in part explain
the ADRs experienced by PMs versus EMs. In this case, ADRs may be
due to the reduced rate of elimination of the accumulated active moi-
ety in plasma seen with repeated dosing in PMs. The extended plasma
half-life for risperidone in CYP2D6 PMs from 2.9 h in EM to 15.1 h in
PMs (Novalbos et al., 2010) combined with a typical dosage of 3.0 to
8.0 mg taken at two time intervals daily, could result in increasing
plasma levels towards toxicity. In support of this, Kang et al. (2009)
demonstrated that CYP3A5 polymorphisms are more likely to inﬂu-
ence the risperidone active moiety. Alternatively, both higher plasma
concentrations of the active moiety (Locatelli et al., 2010) and the
CYP2D6 PM genotype (de Leon et al., 2005a) have been associated
with an increase in the incidence of extrapyramidal symptom (EPS)
ADRs.
4.3. CYP2D6 and risperidone weight gain
An important risperidone related ADR that has received little
pharmacogenetic attention is weight gain. Weight gain has been
found to reduce compliance in patients taking antipsychotics even if
the psychopharmacological treatment is effective (Nasrallah, 2006).
The CYP2D6*10 polymorphism 188CNT was found to be associated
with weight gain in risperidone-treated Chinese patients (Lane et al.,
2006). Interestingly, the association appeared to be stronger in hetero-
zygote individuals (C/T) than in homozygotes (T/T). In the present
study, CYP2D6 defective polymorphisms were not associated with
weight gain and only 1 of the 7 patients experiencing weight gain was
a PM. In patientswho gainedmore than 5 kg, risperidone-relatedmove-
ment disorders were not observed. This is an interesting observation,
which may have a genetic component.
Factors unrelated to risperidone treatment or genetic predisposition
may also have inﬂuenced weight gain. Such factors may include com-
fort/social eating, contraceptives, taste changes, changes in diet and
the administered medication itself.
4.4. Inverse relationship between movement disorders and weight gain
The statistical observation of an inverse relationship between move-
ment disorders and weight gain should be met with caution. Clinically,
movement disorders tend to present early in treatment and are treatedor overcome by dosage titration. Weight gain typically has a slow onset
(Hellings et al., 2001) and the patients who have experienced
risperidone-related weight gain have overcome the initial risperidone-
related ADRs.4.5. Concomitant medication
Many of the patients sampled in this naturalistic cohort were taking
concomitant medication which may have confounded the ADRs ob-
served. The P450 Drug Interaction Table posted by the Division of Clin-
ical Pharmacology at Indiana University offers valuable information
regarding drug substrates, inducers and inhibitors of the CYP enzymes
(Flockhart, 2009). Applying this information to the current cohort al-
lows one to evaluate the effect of concomitant medication. Citalopram,
ﬂuoxetine, imipramine, paroxetine and propranolol were prescribed
concomitantly to some of the patients in this cohort and are listed as
substrates of CYP2D6 (Table 1). More importantly, ﬂuoxetine (Brynne
et al., 1999; Flockhart, 2009) and paroxetine (Bertelsen et al., 2003;
Flockhart, 2009) were listed as strong inhibitors of CYP2D6 causing
more than a 5-fold increase in the plasma area under the curve (AUC)
concentration and/or an 80%decrease in clearance of CYP2D6 substrates
(Flockhart, 2009). It is therefore recommended that these medications
should not be co-administered with risperidone, although sometimes
this is unavoidable.
Three patients were concomitantly prescribed one of these drugs
with risperidone. The ﬁrst patient was an EM on ﬂuoxetine, and re-
ceived 4mg risperidone per day and had a 15/40 score for SAS. The sec-
ond patient was a PM on ﬂuoxetine who received 2 mg risperidone per
day, and scored 9/40 for AIMS and 14/40 for SAS. The third patient was
anEMon paroxetinewho received 6mg risperidone daily, and scored 4/
14 for BAS, 1/40 for SAS and gained 4 kg. These patients, in theory,
should have experienced theworst risperidone-inducedmovement dis-
orders, but this was not the case. Similarly, a different patient was co-
prescribed hydroxyzine, which is listed as an inhibitor of CYP2D6
(Hamelin et al., 1998). This patient received 1 mg risperidone per day,
was an EM and had higher degree of movement disorders than the pre-
vious three patients, scoring 21/40 for AIMS, 9/14 for BAS and 4/40 for
SAS. In this case it would appear that hydrazine could have been con-
tributing to perceived risperidone ADRs, but this was the only example
in the cohort. Finally citalopram, listed as an inhibitor of CYP2D6, which
was discounted previously due to lack of supporting documentation
(Mannheimer et al., 2008), did not appear in this study to increase
movement disorders when co-prescribed with risperidone, although
this should be investigated in a larger cohort. The majority of the pa-
tients who gainedmore than 5 kgwhile on risperidonewere not receiv-
ing concomitant medication, except one patient who gained 45 kg and
who was co-medicated with citalopram.4.6. Additional genes to consider
Other genes that affect risperidone efﬁcacy and cause ADRs have
previously been considered. Genes affecting metabolism (enzymes),
drug or dopamine clearance as well as drug receptor variability could
be responsible for risperidone movement disorders and may be impor-
tant as pharmacogenetic markers. For example, CYP3A5 (Kang et al.,
2009) and ABCB1 (Gunes et al., 2008) have been shown to inﬂuence
the risperidone activemoiety. Genetic variability of phase IImetabolism
by a glutathione S-transferase enzyme coded for by GSTM1 has been as-
sociated with dyskinesia experienced in risperidone-treated patients
(de Leon et al., 2005b). The Ser9Glymutation in theDRD3 dopamine re-
ceptor gene is associatedwith increased risk of dyskinesia in risperidone
treated patients (de Leon et al., 2005b).Weight gain as a result of risper-
idone treatment has been linked to polymorphisms in 5-HT2A, 5-HT2C,
5-HT6 and BDNF (Lane et al., 2006).
45T.M. Dodgen et al. / Applied & Translational Genomics 5 (2015) 40–465. Limitations
We are aware that caution needs to be exercised when interpreting
these results as the numbers are relatively small and there are
confounding factors that have been included in this naturalistic cohort.
Although the aim of this study was to identify PMs from patients
experiencing ADRs, the sample size may not be sufﬁcient to have iden-
tiﬁed such relationship. In some cases large cohorts are needed to ﬁnd
signiﬁcant association (de Leon et al., 2005b). Perhaps if the cohort
size is increased an associationwill be found, but the question is wheth-
er this will be a strong pharmacogenetic marker to reduce ADRs, partic-
ularly in view of the important environmental inﬂuences including
concomitant medication. Although no statistical evidence was found,
concomitant medication may have confounded the results in our
study and this will need to be considered in future studies of larger co-
hort size. Measuring blood concentrations of risperidone and its active
metabolite in future studies may help to clarify the role of potential in-
termediaries in the hypothesised connection between genetic and clin-
ical phenotypes.
6. Conclusion
CYP2D6 polymorphisms appeared not to associate with risperidone
ADRs (movement disorders and weight gain) in this pilot cohort of
risperidone-treated South African patients. Weight gain andmovement
disorders appeared not to be experienced simultaneously when pa-
tients were treated with risperidone, but this might have been a pecu-
liarity of the cohort. A novel CYP2D6 mutation, which may have
clinical relevance, was identiﬁed in this cohort. A larger cohort would
be valuable to conﬁrm the results of this study.
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